Medindia

X

Canada May Not Permit Bextra To Reenter Market

by Medindia Content Team on  December 19, 2005 at 11:24 AM Drug News   - G J E 4
Canada May Not Permit Bextra To Reenter Market
Health Canada has announced a ban on the anti-inflammatory drug Bextra, meant for those who suffer from arthritis. The benefits derived from the drug were outweighed by the cardiovascular risks, including the possibility of triggering strokes and heart attacks, according to an expert safety panel.
Advertisement

The drug is also known to cause severe skin reactions which can even prove to be fatal. Pfizer had earlier withdrawn the drug which belongs to the cox-2 inhibitors class after incidences of skin reactions in the country. Pfizer Canada however is of the view that the drug should be made available to those who continue to benefit from it.

Advertisement
The regulators in Europe and Canada have also voiced strong objections to the drug, as its safety is under doubt. The total sales Bextra in 2004 across the world was at US$ 1.3 billion. Vioxx, manufactured Merck & Co. Inc was also withdrawn from the market for similar reasons. This drug however has a chance of being permitted to enter the Canadian market again.
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All